In breast cancers, however, BIG3 captures PHB2 through its KPNA (KPNA1, KPNA5, and KPNA6)-binding region(s), thereby inhibiting the E2-dependent suppressive ability of PHB2. Here, PHB2 is linked to breast carcinoma.